secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2025-08-01T23:59:59+00:00
Accession:  0000950103-25-009701
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal completes $2.7B refinancing: $2.1B term loan and $600M notes
-------------------------------------------------------------------

- Borrowed $2.1B of new seven-year term B loans due Aug 2032; margin SOFR+3.50% or base+2.50%.
- Issued $600M 6.875% senior secured notes due Aug 2032; proceeds used to refinance existing debt.
- Amended ABL facility extends maturity to Aug 2030; $600M revolving commitments unchanged.
- Refinanced existing $2.26B term loans in full and repaid all ABL borrowings with net proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000095010325009701/0000950103-25-009701-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000095010325009701/dp232462_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-25-009701

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer